Roche touts full data for drug in first-line PIK3CA-mutated breast cancer

Roche’s breast cancer combination of inavolisib plus palbociclib and fulvestrant showed off new data Friday, with the company touting a 57% reduction in the risk of disease progression or death in patients with PIK3CA-mutated HR-positive HER2-negative breast cancer.

The big pharma is hoping inavolisib is the first approval for a…
Click here to view original post